Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

Jens Huober, Eileen Holmes, José Baselga, Evandro de Azambuja, Michael Untch, Debora Fumagalli, Severine Sarp, I. Láng, Ian Smith, Frances Boyle, Binghe Xu, Christophe Lecocq, Hans Wildiers, Christelle Jouannaud, John Hackman, Lokanatha Dasappa, Eva Ciruelos, Juan Carlos Toral Pena, Hryhoriy Adamchuk, T. HickishLorena de la Pena, Christian Jackisch, Richard D. Gelber, Martine Piccart-Gebhart, Serena Di Cosimo

Research output: Contribution to journalArticle

Abstract

Background: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti–human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel. The event-free survival (EFS) and overall survival (OS) by the treatment arms L + T vs. T and L vs. T and the relationship between pCR and EFS/OS both in the whole study population and according to hormone receptor–negative and hormone receptor–positive cohorts after a median follow-up of 6.7 years were assessed. Patients and methods: Four hundred fifty-five patients with HER2-positive early breast cancer randomly received L 1500 mg/day (n = 154), T (common dose, n = 149) or L 1000 mg/day plus T (n = 152) for 6 weeks, followed by the assigned anti-HER2 treatment combined with paclitaxel weekly × 12. After surgery, patients received 3 cycles of fluorouracil, epirubicin and cyclophosphamide. The primary end-point was pCR (ypT0/is; for current analysis, it is ypT0/is ypN0), and the secondary end-points were EFS and OS. Results: Six-year EFS rates were 67%, 67% and 74% with L, T and L + T, respectively (L vs T: hazard ratio [HR], 0.98 [95% confidence interval {CI}, 0.64–1.51; P = .93]; L + T vs T: HR, 0.81 [95% CI, 0.52–1.26; P = .35]). Six-Year OS rates were 82%, 79% and 85% for L, T and L + T, respectively (L vs T: HR, 0.85 [95% CI, 0.49–1.46; P = .56]; L + T vs T: HR, 0.72 [95% CI, 0.41–1.27; P = .26]). In landmark analyses, patients with a pCR had a significantly higher 6-year EFS (77% and 65%) and OS (89% and 77%) compared with those without a pCR for both overall and the hormone receptor–negative cohort. Conclusion: Achieving a pCR is important in HER2-positive disease and translates into better long-term outcome with regard to EFS and OS.

Original languageEnglish
Pages (from-to)169-177
Number of pages9
JournalEuropean Journal of Cancer
Volume118
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Phase III Clinical Trials
Disease-Free Survival
Outcome Assessment (Health Care)
Breast Neoplasms
Survival
Paclitaxel
Confidence Intervals
Hormones
Survival Rate
Epirubicin
Epidermal Growth Factor Receptor
Fluorouracil
Cyclophosphamide
Therapeutics
Population

Keywords

  • Breast cancer
  • HER2 positive
  • Neoadjuvant

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Survival outcomes of the NeoALTTO study (BIG 1–06) : updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. / Huober, Jens; Holmes, Eileen; Baselga, José; de Azambuja, Evandro; Untch, Michael; Fumagalli, Debora; Sarp, Severine; Láng, I.; Smith, Ian; Boyle, Frances; Xu, Binghe; Lecocq, Christophe; Wildiers, Hans; Jouannaud, Christelle; Hackman, John; Dasappa, Lokanatha; Ciruelos, Eva; Toral Pena, Juan Carlos; Adamchuk, Hryhoriy; Hickish, T.; de la Pena, Lorena; Jackisch, Christian; Gelber, Richard D.; Piccart-Gebhart, Martine; Di Cosimo, Serena.

In: European Journal of Cancer, Vol. 118, 01.09.2019, p. 169-177.

Research output: Contribution to journalArticle

Huober, J, Holmes, E, Baselga, J, de Azambuja, E, Untch, M, Fumagalli, D, Sarp, S, Láng, I, Smith, I, Boyle, F, Xu, B, Lecocq, C, Wildiers, H, Jouannaud, C, Hackman, J, Dasappa, L, Ciruelos, E, Toral Pena, JC, Adamchuk, H, Hickish, T, de la Pena, L, Jackisch, C, Gelber, RD, Piccart-Gebhart, M & Di Cosimo, S 2019, 'Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer', European Journal of Cancer, vol. 118, pp. 169-177. https://doi.org/10.1016/j.ejca.2019.04.038
Huober, Jens ; Holmes, Eileen ; Baselga, José ; de Azambuja, Evandro ; Untch, Michael ; Fumagalli, Debora ; Sarp, Severine ; Láng, I. ; Smith, Ian ; Boyle, Frances ; Xu, Binghe ; Lecocq, Christophe ; Wildiers, Hans ; Jouannaud, Christelle ; Hackman, John ; Dasappa, Lokanatha ; Ciruelos, Eva ; Toral Pena, Juan Carlos ; Adamchuk, Hryhoriy ; Hickish, T. ; de la Pena, Lorena ; Jackisch, Christian ; Gelber, Richard D. ; Piccart-Gebhart, Martine ; Di Cosimo, Serena. / Survival outcomes of the NeoALTTO study (BIG 1–06) : updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. In: European Journal of Cancer. 2019 ; Vol. 118. pp. 169-177.
@article{f0e9555160c24011accddb88c630e16e,
title = "Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer",
abstract = "Background: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti–human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel. The event-free survival (EFS) and overall survival (OS) by the treatment arms L + T vs. T and L vs. T and the relationship between pCR and EFS/OS both in the whole study population and according to hormone receptor–negative and hormone receptor–positive cohorts after a median follow-up of 6.7 years were assessed. Patients and methods: Four hundred fifty-five patients with HER2-positive early breast cancer randomly received L 1500 mg/day (n = 154), T (common dose, n = 149) or L 1000 mg/day plus T (n = 152) for 6 weeks, followed by the assigned anti-HER2 treatment combined with paclitaxel weekly × 12. After surgery, patients received 3 cycles of fluorouracil, epirubicin and cyclophosphamide. The primary end-point was pCR (ypT0/is; for current analysis, it is ypT0/is ypN0), and the secondary end-points were EFS and OS. Results: Six-year EFS rates were 67{\%}, 67{\%} and 74{\%} with L, T and L + T, respectively (L vs T: hazard ratio [HR], 0.98 [95{\%} confidence interval {CI}, 0.64–1.51; P = .93]; L + T vs T: HR, 0.81 [95{\%} CI, 0.52–1.26; P = .35]). Six-Year OS rates were 82{\%}, 79{\%} and 85{\%} for L, T and L + T, respectively (L vs T: HR, 0.85 [95{\%} CI, 0.49–1.46; P = .56]; L + T vs T: HR, 0.72 [95{\%} CI, 0.41–1.27; P = .26]). In landmark analyses, patients with a pCR had a significantly higher 6-year EFS (77{\%} and 65{\%}) and OS (89{\%} and 77{\%}) compared with those without a pCR for both overall and the hormone receptor–negative cohort. Conclusion: Achieving a pCR is important in HER2-positive disease and translates into better long-term outcome with regard to EFS and OS.",
keywords = "Breast cancer, HER2 positive, Neoadjuvant",
author = "Jens Huober and Eileen Holmes and Jos{\'e} Baselga and {de Azambuja}, Evandro and Michael Untch and Debora Fumagalli and Severine Sarp and I. L{\'a}ng and Ian Smith and Frances Boyle and Binghe Xu and Christophe Lecocq and Hans Wildiers and Christelle Jouannaud and John Hackman and Lokanatha Dasappa and Eva Ciruelos and {Toral Pena}, {Juan Carlos} and Hryhoriy Adamchuk and T. Hickish and {de la Pena}, Lorena and Christian Jackisch and Gelber, {Richard D.} and Martine Piccart-Gebhart and {Di Cosimo}, Serena",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.ejca.2019.04.038",
language = "English",
volume = "118",
pages = "169--177",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Survival outcomes of the NeoALTTO study (BIG 1–06)

T2 - updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

AU - Huober, Jens

AU - Holmes, Eileen

AU - Baselga, José

AU - de Azambuja, Evandro

AU - Untch, Michael

AU - Fumagalli, Debora

AU - Sarp, Severine

AU - Láng, I.

AU - Smith, Ian

AU - Boyle, Frances

AU - Xu, Binghe

AU - Lecocq, Christophe

AU - Wildiers, Hans

AU - Jouannaud, Christelle

AU - Hackman, John

AU - Dasappa, Lokanatha

AU - Ciruelos, Eva

AU - Toral Pena, Juan Carlos

AU - Adamchuk, Hryhoriy

AU - Hickish, T.

AU - de la Pena, Lorena

AU - Jackisch, Christian

AU - Gelber, Richard D.

AU - Piccart-Gebhart, Martine

AU - Di Cosimo, Serena

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti–human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel. The event-free survival (EFS) and overall survival (OS) by the treatment arms L + T vs. T and L vs. T and the relationship between pCR and EFS/OS both in the whole study population and according to hormone receptor–negative and hormone receptor–positive cohorts after a median follow-up of 6.7 years were assessed. Patients and methods: Four hundred fifty-five patients with HER2-positive early breast cancer randomly received L 1500 mg/day (n = 154), T (common dose, n = 149) or L 1000 mg/day plus T (n = 152) for 6 weeks, followed by the assigned anti-HER2 treatment combined with paclitaxel weekly × 12. After surgery, patients received 3 cycles of fluorouracil, epirubicin and cyclophosphamide. The primary end-point was pCR (ypT0/is; for current analysis, it is ypT0/is ypN0), and the secondary end-points were EFS and OS. Results: Six-year EFS rates were 67%, 67% and 74% with L, T and L + T, respectively (L vs T: hazard ratio [HR], 0.98 [95% confidence interval {CI}, 0.64–1.51; P = .93]; L + T vs T: HR, 0.81 [95% CI, 0.52–1.26; P = .35]). Six-Year OS rates were 82%, 79% and 85% for L, T and L + T, respectively (L vs T: HR, 0.85 [95% CI, 0.49–1.46; P = .56]; L + T vs T: HR, 0.72 [95% CI, 0.41–1.27; P = .26]). In landmark analyses, patients with a pCR had a significantly higher 6-year EFS (77% and 65%) and OS (89% and 77%) compared with those without a pCR for both overall and the hormone receptor–negative cohort. Conclusion: Achieving a pCR is important in HER2-positive disease and translates into better long-term outcome with regard to EFS and OS.

AB - Background: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate compared with the anti–human epidermal growth factor receptor 2 (HER2) agent alone plus paclitaxel. The event-free survival (EFS) and overall survival (OS) by the treatment arms L + T vs. T and L vs. T and the relationship between pCR and EFS/OS both in the whole study population and according to hormone receptor–negative and hormone receptor–positive cohorts after a median follow-up of 6.7 years were assessed. Patients and methods: Four hundred fifty-five patients with HER2-positive early breast cancer randomly received L 1500 mg/day (n = 154), T (common dose, n = 149) or L 1000 mg/day plus T (n = 152) for 6 weeks, followed by the assigned anti-HER2 treatment combined with paclitaxel weekly × 12. After surgery, patients received 3 cycles of fluorouracil, epirubicin and cyclophosphamide. The primary end-point was pCR (ypT0/is; for current analysis, it is ypT0/is ypN0), and the secondary end-points were EFS and OS. Results: Six-year EFS rates were 67%, 67% and 74% with L, T and L + T, respectively (L vs T: hazard ratio [HR], 0.98 [95% confidence interval {CI}, 0.64–1.51; P = .93]; L + T vs T: HR, 0.81 [95% CI, 0.52–1.26; P = .35]). Six-Year OS rates were 82%, 79% and 85% for L, T and L + T, respectively (L vs T: HR, 0.85 [95% CI, 0.49–1.46; P = .56]; L + T vs T: HR, 0.72 [95% CI, 0.41–1.27; P = .26]). In landmark analyses, patients with a pCR had a significantly higher 6-year EFS (77% and 65%) and OS (89% and 77%) compared with those without a pCR for both overall and the hormone receptor–negative cohort. Conclusion: Achieving a pCR is important in HER2-positive disease and translates into better long-term outcome with regard to EFS and OS.

KW - Breast cancer

KW - HER2 positive

KW - Neoadjuvant

UR - http://www.scopus.com/inward/record.url?scp=85069972162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069972162&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2019.04.038

DO - 10.1016/j.ejca.2019.04.038

M3 - Article

AN - SCOPUS:85069972162

VL - 118

SP - 169

EP - 177

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -